Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial.
Kenric Rui-Pin FanMani BaskaranMonisha E NongpiurHla Mynt HtoonJohn Mark S de LeonShamira A PereraMichael BelkinTin AungPublished in: Acta ophthalmologica (2019)
After APAC, there was no difference in VF progression (or RNFL thickness change) between Cop-1 and placebo groups. However, there was improvement of MD in Cop-1 treated patients.
Keyphrases
- clinical trial
- double blind
- placebo controlled
- end stage renal disease
- newly diagnosed
- phase iii
- ejection fraction
- chronic kidney disease
- liver failure
- study protocol
- phase ii
- prognostic factors
- high resolution
- squamous cell carcinoma
- open label
- patient reported outcomes
- respiratory failure
- cerebral ischemia
- brain injury